In the era of personalized medicine, HER2-positive breast cancer turned to be a curable disease with multiple effective treatment options creating an urgent need for more comprehensive methods for data analysis and biomarkers to select the right treatment for the right patient. Here, ERBB2 is linked to breast cancer.